Today, we shared positive Phase 2b TYDAL-TIMI 78 Part A data for MAR001 in a late-breaking session at #AHA2026, and it was simultaneously published in @NEJM.
These results provide compelling clinical validation of ANGPTL4 inhibition as a novel approach to lowering triglycerides and improving metabolic function.
We’re particularly encouraged by the greater triglyceride lowering seen in people with higher baseline levels, reinforcing our confidence in the potential of MAR001/MAR005 for severe hypertriglyceridemia (sHTG).
Next up: Part B of our Phase 2b program in sHTG.
Read the details: mareatx.com/press-releases…
NEJM Publication: nejm.org/doi/full/10.10…
These results provide compelling clinical validation of ANGPTL4 inhibition as a novel approach to lowering triglycerides and improving metabolic function.
We’re particularly encouraged by the greater triglyceride lowering seen in people with higher baseline levels, reinforcing our confidence in the potential of MAR001/MAR005 for severe hypertriglyceridemia (sHTG).
Next up: Part B of our Phase 2b program in sHTG.
Read the details: mareatx.com/press-releases…
NEJM Publication: nejm.org/doi/full/10.10…